Ariane Laparra

Ariane Laparra

Auto-generated profile, based on publicly available information

Ariane Laparra

Institut Gustave Roussy 4 Department of Medicine Villejuif, France

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 May 2024 in European Journal of Cancer
Verified
Journal Article
Closed access
AGArthur GERAUD
Arthur GERAUD
THThomas Hueso
Thomas Hueso
ALAriane Laparra
Ariane Laparra
NBNaike Bige
Naike Bige
KOKaissa Ouali
Kaissa Ouali
Jean Marie MichotJean Marie Michot
Jean Marie Michot

26 August 2023 in European Journal of Cancer
Verified
Journal Article
Closed access
EAEmily Alouani
Emily Alouani
ALAriane Laparra
Ariane Laparra
APAudrey Perret
Audrey Perret
MSMadonna Sakkal
Madonna Sakkal
SMSabine Messayke
Sabine Messayke
Jean Marie MichotJean Marie Michot
Jean Marie Michot

18 February 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
JFJean-Eudes Fahrner
Jean-Eudes Fahrner
ILImran Lahmar
Imran Lahmar
AGAnne-Gaëlle Goubet
Anne-Gaëlle Goubet
YHYacine Haddad
Yacine Haddad
ACAgathe Carrier
Agathe Carrier
LZLaurence Zitvogel
Laurence Zitvogel
Vaccination against coronavirus disease 2019 (COVID-19) relies on the in-depth understanding of protective immune responses to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). We characterized the polarity and specificity of memory T cells directed against SARS-CoV-2 viral lysates and peptides to determine correlates with spontaneous, virus-elicited, or vaccine-induced protection against COVID-19 in disease-free and cancer-bearing individuals. A disbalance between type 1 and 2 cytokine release was associated with high susceptibility to COVID-19. Individuals susceptible to infection exhibited a specific deficit in the T helper 1/T cytotoxic 1 (Th1/Tc1) peptide repertoire affecting the receptor binding domain of the spike protein (S1-RBD), a hotspot of viral mutations. Current vaccines triggered Th1/Tc1 responses in only a fraction of all subject categories, more effectively against the original sequence of S1-RBD than that from viral variants. We speculate that the next generation of vaccines should elicit Th1/Tc1 T-cell responses against the S1-RBD domain of emerging viral variants. Significance: This study prospectively analyzed virus-specific T-cell correlates of protection against COVID-19 in healthy and cancer-bearing individuals. A disbalance between Th1/Th2 recall responses conferred susceptibility to COVID-19 in both populations, coinciding with selective defects in Th1 recognition of the receptor binding domain of spike. See related commentary by McGary and Vardhana, p. 892. This article is highlighted in the In This Issue feature, p. 873

23 September 2025 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
RGRomain Guitton
Romain Guitton
ALAriane Laparra
Ariane Laparra
NCNoemie Chanson
Noemie Chanson
SCStephane Champiat
Stephane Champiat
FDFrancois-Xavier Danlos
Francois-Xavier Danlos
OLOlivier Lambotte
Olivier Lambotte
Background: The optimal dosing regimen for immune checkpoint blockade (ICB) remains a critical question in oncology. Although immune-related adverse events (irAEs) are common with ICB, the incidence and severity of irAEs following a single dose of anti-programmed death-ligand 1 (PD-(L)1) blockade have not yet been investigated. Methods: We conducted a single-center prospective cohort study at Gustave Roussy (Villejuif, France), based on a population of patients with advanced or metastatic cancer, using data from the French Registre des Effets Indésirables Sévères des Anticorps Monoclonaux (REISAMIC) registry, a pharmacovigilance database dedicated to irAEs. Between December 2014 and December 2023, we included adults with solid or hematologic malignancies who presented with irAEs after the first infusion of anti-PD-(L)1 therapy, regardless of the treatment indication, and before the administration of the second dose of ICB. The main outcomes included the incidence and characteristics of irAEs, particularly severe (grade 3–4) and fatal (grade 5) events. Results: Of the 3565 patients prospectively followed in REISAMIC, 70 (1.96%) experienced irAEs following a single infusion. Of these 70 patients, severe irAEs (grade 3–4) occurred in 20 patients (37.1%), and fatal irAEs (grade 5) were recorded in three cases (4.3%), indicating significant toxicity risks. The most frequently affected organ systems were the skin (14 (20%)), musculoskeletal system (11 (15.7%)), endocrine system (9 (12.9%)), and cardiovascular system (9 (12.9%)). Most irAEs developed within 20 days after treatment, with a median onset time of 14 days (IQR, 5–21). Multiorgan toxicities were observed in 10% of patients. Despite the severity, no predictive markers for fatality, multiorgan involvement, or early onset were identified, including pre-existing autoimmune conditions. Conclusions: This study underscores the notable risk of severe and fatal irAEs following a single dose of anti-PD-(L)1 therapy in patients with advanced/metastatic cancer. The absence of predictive markers for fatality, multiorgan toxicities, or early onset highlights the need for enhanced patient monitoring during the initial treatment phase. Further research is needed to optimize dosing regimens, balancing safety and efficacy for safer clinical use of immune checkpoint blockade.

17 September 2025 in ESMO Open
Verified
Journal Article
Open access
SCS. Champiat
S. Champiat
KOK. Ouali
K. Ouali
ALA. Laparra
A. Laparra
ACAndreas Charalambous
Andreas Charalambous
MPM. Di Palma
M. Di Palma
FSFlorian Scotté
Florian Scotté
The conventional drug development pathway in oncology, spanning 10-15 years, has long been slow, costly, and complex, often marked by late-stage failures due to efficacy or safety concerns. We aimed to develop this position paper, based on a literature review and by sharing experience, skills, and works of the different co-authors, in order to propose a new approach to the clinical trials' process. In the past decade, the field has undergone major transformation. Innovative trial designs and fast-track regulatory pathways, such as priority review, breakthrough designation, accelerated approval, and fast-track processes, have significantly shortened timelines from phase I to market approval. While these approaches have enabled quicker access to promising therapies, they have also exposed gaps in postmarketing safety and highlighted the need for tailored adverse event management strategies. These emerging safety challenges call for multidisciplinary evaluation and the integration of advanced monitoring technologies. This manuscript introduces a comprehensive, adaptive fast-track safety evaluation framework designed to support oncology drug development. It aims to enhance patient safety while preserving the benefits of accelerated regulatory pathways.

26 August 2024 in JMIR Research Protocols
Verified
Journal Article
Open access
MFMaria Alice Franzoi
Maria Alice Franzoi
APArnaud Pagès
Arnaud Pagès
LPLoula Papageorgiou
Loula Papageorgiou
AMAntonio Di Meglio
Antonio Di Meglio
ALAriane Laparra
Ariane Laparra
IVInes Vaz-Luis
Ines Vaz-Luis
Background: Supportive care (SC) refers to the prevention and management of complications of cancer and its treatment. While it has long been recognized as an important cancer care delivery component, a high proportion of patients face unaddressed SC needs, calling for innovative approaches to deliver SC. Objective: The objective of this master protocol is to evaluate the implementation of different integrated proactive SC pathways across the cancer care continuum in our institution (Gustave Roussy, Villejuif, France). Pathways studied in this master protocol may occur shortly after diagnosis to prevent treatment-related burden; during treatment to monitor the onset of toxicities and provide timely symptom management; and after treatment to improve rehabilitation, self-management skills, and social reintegration. Methods: This study is guided by the Reach, Effectiveness, Adoption, Implementation, and Maintenance framework. The primary objective is to evaluate the impact of SC pathways on patients’ distress and unmet needs after 12 weeks, measured by the National Comprehensive Cancer Network’s Distress Thermometer and Problem List. Secondary objectives will focus on the pathways (macrolevel) and each SC intervention (microlevel), evaluating their reach (administrative data review of the absolute number and proportion of clinical and sociodemographic characteristics of patients included in the pathways); short-term and long-term efficacy through their impact on quality of life (EQ-5D-5L and the 30-item European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire) and symptom burden (MD Anderson Symptom Inventory, Hospital Anxiety and Depression Scale, Insomnia Severity Index, and 22-item European Organization for Research and Treatment of Cancer Sexual Health Questionnaire); adoption by patients and providers (administrative data review of SC referrals and attendance or use of SC strategies); barriers to and leverage for implementation (surveys and focus groups with patients, providers, and the hospital organization); and maintenance (cost-consequence analysis). Pilot evaluations with a minimum of 70 patients per pathway will be performed to generate mean Distress Thermometer scores and SDs informing the calculation of formal sample size needed for efficacy evaluation (cohorts will be enriched accordingly). Results: The study was approved by the ethics committee, and as of February 2024, a total of 12 patients were enrolled. Conclusions: This study will contribute toward innovative models of SC delivery and will inform the implementation of integrated SC pathways of care. Trial Registration: ClinicalTrials.gov NCT06479057; https://clinicaltrials.gov/study/NCT06479057 International Registered Report Identifier (IRRID): PRR1-10.2196/52841